Get the Daily Brief
Latest Biotech News
AI life‑science funding heats up: Insilico IPO, Edison seed round
AI drug‑discovery and research‑software financing accelerated as Insilico Medicine filed to raise HK$2.27 billion (about $292M) in a Hong Kong IPO to advance its clinical pipeline and generative...
White House finalizes nine MFN drug deals — pricing and policy move
The White House announced 'most favored nation' (MFN) style agreements with nine major drugmakers — including Amgen, BMS, Gilead and Novartis — in an end‑of‑year policy push to align some U.S....
JAX completes NYSCF unification — new nonprofit research engine
The Jackson Laboratory (JAX) completed its acquisition of the New York Stem Cell Foundation (NYSCF) and launched a unified organization in New York City, integrating JAX’s genetics and mouse‑model...
Gene‑therapy access vs. manufacturing scrutiny: nonprofit rescue, Catalent 483s
A nonprofit organization successfully brought an abandoned rare‑disease gene therapy to market, illustrating alternative models to rescue small or orphan programs that big pharma has shelved....
BioMarin to buy Amicus: $4.8B bet on Fabry and Pompe franchises
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion in an all-cash transaction that the companies expect to close in the second quarter of 2026. The deal transfers two marketed...
FDA halts Merck–Daiichi ADC trial: deaths trigger partial hold
Regulators and sponsors paused a Phase III study of the antibody‑drug conjugate I‑Dxd after an unexpectedly high incidence of fatal interstitial lung disease (ILD) events. Daiichi Sankyo...
Cytokinetics wins FDA green light: first U.S. drug approved
The FDA approved Cytokinetics’ Myqorzo, the company’s first U.S. drug, for obstructive hypertrophic cardiomyopathy (oHCM). The approval closes a 27‑year effort by the biotech and establishes...
Takeda’s TYK2 drug clears Phase 3—regulatory filings planned
Takeda reported that zasocitinib, a TYK2 inhibitor acquired via a major deal, met co‑primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said more than half...
Lilly’s oral GLP-1 hits maintenance goal — review accelerated
Eli Lilly disclosed positive top‑line results from the Phase 3 Attain‑Maintain trial: its oral GLP‑1 receptor agonist orforglipron met primary and key secondary endpoints for weight maintenance...
CEPI backs Moderna’s H5 mRNA shot: funds Phase 3 push
Moderna secured up to $54.3 million from CEPI to advance its mRNA H5 influenza vaccine candidate, mRNA‑1018, into Phase 3 testing. The funding restores external support after the company’s earlier...
Parse and Codebreaker join to map variant effects with single‑cell readouts
Parse Biosciences and Codebreaker Labs launched a collaboration to combine engineered variant libraries with high‑throughput single‑cell transcriptomics to experimentally characterize how genetic...
Epigenovo pushes scFFPE‑ATAC: single‑cell chromatin assay for FFPE tissue
Epigenovo, a Uppsala University spinout, is commercializing scFFPE‑ATAC, a single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) samples. The startup...
Galux inks AI pact with Boehringer – aim to design purpose‑specific proteins
Galux, a South Korean AI‑driven protein design biotech, signed a research agreement with Boehringer Ingelheim to validate AI approaches for designing purpose‑specific therapeutic proteins. The...
Brinsupri failure slashes Insmed market cap – program reset
Insmed reported a failed Phase 2b study of brensocatib (Brinsupri) in chronic rhinosinusitis, prompting a sell‑off that cut the company's market capitalization and ended a recent streak of...
BioMarin buys Amicus for $4.8B: gains Fabry and Pompe drugs
BioMarin agreed to acquire Amicus Therapeutics in an all‑cash deal valued at about $4.8 billion, securing two marketed rare‑disease products for Fabry and Pompe diseases and U.S. rights to a phase...
FDA clears Cytokinetics’ heart drug — company wins first U.S. approval
The U.S. Food and Drug Administration approved Cytokinetics’ new therapy Myqorzo for obstructive hypertrophic cardiomyopathy, marking the biotech’s first U.S. drug approval. Company disclosures...
ADC program...FDA pauses Daiichi‑Merck Phase 3 after deaths
Regulators and sponsors paused enrollment in the Phase 3 IDeate‑Lung02 study of the antibody‑drug conjugate ifinatamab deruxtecan after a higher‑than‑anticipated incidence of grade‑5 interstitial...
Takeda’s TYK2 pill succeeds in Phase 3 — filings planned for 2026
Takeda reported that zasocitinib, its TYK2 inhibitor acquired in a multibillion‑dollar deal, met co‑primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said...
Lilly’s oral GLP‑1 maintains weight loss — Phase 3 meets endpoints
Eli Lilly reported positive top‑line results from the Phase 3 Attain‑Maintain trial of orforglipron, an oral GLP‑1 receptor agonist, showing superior weight maintenance over 52 weeks versus...
Moderna gets CEPI backing: $54M to advance H5 pandemic vaccine
Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its H5 avian influenza mRNA vaccine mRNA‑1018 into Phase 3 testing. The grant follows...